Author/Authors :
Rezaei Tavirani, M Clinical Proteomics Research Center - Faculty of Paramedical Sciences - Shahid Beheshti University of Medical Sciences, Tehran - Skin Research Center - Shahid Beheshti University of Medical Sciences, Tehran , Zali, H Clinical Proteomics Research Center - Faculty of Paramedical Sciences - Shahid Beheshti University of Medical Sciences, Tehran , Nasiri, S Skin Research Center - Shahid Beheshti University of Medical Sciences, Tehran , Shokrgozar, MA National Cell Bank of Iran - Pasteur Institute of Iran, Tehran
Abstract :
Background: Chemotherapy by using agents such as etoposide is a common way for
inhibition of tumors. This treatment is accompanied by many undesirable side effects.
Calprotectin is an abundant protein in the neutrophil cytosol, it has growth-inhibitory
and apoptosis-inducing activities against various cell types such as tumor cells. In this
study to introduce calprotectin as a suitable substitute anticancer, its growth
inhibitory effect on human gastric adenocarcinoma cell line (AGS) and human
foreskin fibroblast cells (HFFF) is compared to etoposide effect on these two cell
lines.
Methods: Calprotectin was purified from human neutrophil by chromatography
methods. AGS and HFFF cell lines were used. These cells were maintained in RPMI
1640 medium supplemented with 10% FCS in a humidified incubator (37 ºC & 5%
CO2). AGS cells (10000 cells per well) were exposed to the different concentrations
of calprotectin and etoposide for 24 and 48 h. MTT assay was used for evaluation
of cytotoxicity.
Results: Results indicate that calprotectin has more potent anticancer activity in
comparison to the etoposide but it has nearly similar inhibitory effect on the
proliferation of fibroblast cells.
Conclusion: Since calprotectin affect about 20 times more than etoposide on
cancer cells, without any additional side effect, it can be concluded that it is a
suitable candidate to be studied as anticancer drug.